Form 4: Mirum Pharmaceuticals Executive Acquires Shares Through Employee Stock Purchase Plan

Pamela Vig, Chief Scientific Officer of Mirum Pharmaceuticals, acquired 94 shares of common stock through the company's Employee Stock Purchase Plan on May 10, 2024.

Summary

• Pamela Vig, the Chief Scientific Officer of Mirum Pharmaceuticals, acquired 94 shares of common stock on May 10, 2024.
• The acquisition was made through the company's Employee Stock Purchase Plan at a price of $21.046 per share.
• Following the transaction, Ms. Vig directly owns 27,406 shares of Mirum Pharmaceuticals' common stock.
• Ms. Vig also indirectly owns 75,000 shares through The Vig-Ancock Family Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction (executive stock purchase) which is generally viewed as a sign of confidence, but it's not a major event.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Executive stock purchases are common and often viewed as a positive signal, reflecting the executive's belief in the company's value and future performance. It's a routine part of corporate governance and compensation.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates